This is the text extract for May Tender Notification, browse documents here.

---

31 May 2010

TENDER RESULTS

The PHARMAC Board (or Chief Executive under delegated authority) has resolved to accept and decline tenders for Sole Subsidised Supply and Hospital Supply Status for some of the products included in the Invitation to Tender dated 4 December 2009. Please also refer to the March and April notifications for tenders awarded to listed pharmaceuticals with subsidy changes on 1 July 2010. These notifications can be found on our website - http://www.pharmac.govt.nz/suppliers/proposals/tenders. Some of the pharmaceuticals that will be delisted when the period of sole supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts until such time as the pharmaceuticals are delisted and PHARMAC will continue to subsidise their pharmaceuticals accordingly. Product Notification Forms Please note that for all changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H) suppliers are required to notify PHARMAC and the Guild by 4pm 11th June 2010. More information and product notification forms can be downloaded from our website – www.pharmac.govt.nz/schedule.asp. Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule 1. Tenders awarded to listed pharmaceuticals where no other brand is listed – subsidy changes (where applicable) on 1 July 2010 and Sole Supply Status commences 1 October 2010.

The decisions were as follows:

Chemical Name Cefaclor monohydrate Ferrous sulphate

Presentation; Pack size and type Grans for oral liq 125 mg per 5 ml; 100 ml, bottle Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml); 500 ml, bottle

Current Subsidy $3.92 $10.30

New tender subsidy $3.53 $10.30

Sole supply brand (Supplier) Ranbaxy-Cefaclor (Douglas) Ferodan (Mylan)

2. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for tender winning brand at the tender subsidy will occur on 1 July 2010, reference pricing of non-tender winning brand will occur on 1 September 2010 and Sole Subsidised Supply commences on 1 December 2010.

The decisions were as follows:

Chemical Name

Presentation; Pack size and type

Current New Subsidy tender and price subsidy $12.95 $36.48 per per 200 500 ml* ml $19.80 per 2,000 ml** $17.86

Sole supply brand (Supplier) MidWest (MidWest)

Brands affected by reference pricing and delisting PSM (API Consumer) David Craig (Multichem) ABM (ABM) MidWest (MidWest) PSM (API Consumer)

Coal tar

Soln BP; 200 ml, bottle

Glycerol

Liquid, 2,000 ml, bottle

healthE (Jaychem)

A351107 - qA15909

---

*There are two different subsidies. The subsidy indicated reflects the fully funded product. **There are two different subsidies. The subsidy indicated reflects the lower subsidy.

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule 3. Tenders awarded to listed pharmaceuticals where only the current brand is listed – price changes for hospital tender winning brands of the pharmaceuticals will occur in Section H of the Pharmaceutical Schedule on 1 July 2010; DV Limits will apply from 1 September 2010

The decisions were as follows:

Chemical Name Cefaclor monohydrate Ferrous sulphate

Presentation; Pack size and type Grans for oral liq 125 mg per 5 ml; 100 ml, bottle Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml); 500 ml, bottle

Hospital Supply Brand (Supplier) Ranbaxy- Cefaclor (Douglas) Ferodan (Mylan)

Pack Price $3.53 $10.30

DV Limit 1% 1%

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender dated 21 December 2007 and the Invitation to Tender dated 4 December 2009.

The decisions were as follows:

Chemical Name Abacavir Sulphate Abacavir Sulphate Abacavir Sulphate with Lamivudine Amsacrine Apomorphine Hydrochloride Arsenic Trioxide Bumetanide Calcipotriol Calcipotriol Calcipotriol Calcipotriol Calcipotriol Calcipotriol Carmustine Chlorambucil Cladribine Clotrimazole Clotrimazole Colistin Sulphomethate Dacarbazine Dactinomycin (Actinomycin D) Daunorubicin Ergometrine Maleate Ergotamine Tartrate with Caffeine Etoposide Etoposide Etoposide Phosphate Ferrous Salts Ferrous Salts

Line Item Oral liq 20 mg per ml Tab 300 mg Tab 600 mg with lamivudine 300 mg Inj 75 mg Inj 10 mg per ml Inj 10 mg Tab 1 mg Crm 50 mcg per g (pack size 30 g or less) Crm 50 mcg per g (pack size greater than 30 g) Oint 50 mcg per g (pack size 30 g or less) Oint 50 mcg per g (pack size greater than 30 g) Soln 50 mcg per ml (pack size 30 ml or less) Soln 50 mcg per ml (pack size greater than 30 ml) Inj 100 mg Tab 2 mg Inj 10 mg Pessaries 100 mg with applicator(s) Pessaries 500 mg with applicator(s) Inj 150 mg Inj 50 mg Inj 0.5 mg Inj 20 mg Inj 500 mcg per ml, 1 ml Tab 1 mg with caffeine 100 mg Cap 50 mg Cap 100 mg Inj 100 mg (of etoposide base) Tab (long-acting) Tab (short-acting)

A351107 - qA15909

Page 2 of 4

---

Chemical Name Fluocortolone Caproate with Fluocortolone Pivalate and Cinchocaine Fluocortolone Caproate with Fluocortolone Pivalate and Cinchocaine Fluocortolone Pivalate with Lignocaine Fluocortolone Pivalate with Lignocaine Foscarnet Furosemide Gentamicin Sulphate Glycerol Glyceryl Trinitrate Glyceryl Trinitrate Glycopyrronium Hydralazine Hydrocortisone Butyrate Hydrocortisone with Cinchocaine Hydrocortisone with Cinchocaine Hydrocortisone with Lignocaine, Aluminium and Zinc Hydrocortisone with Lignocaine, Aluminium and Zinc Ibuprofen Ibuprofen Ibuprofen Imipramine Hydrochloride Imipramine Hydrochloride Imipenem with Cilastatin Ketamine Hydrochloride Ketamine Hydrochloride Ketamine Hydrochloride Ketamine Hydrochloride Ketamine Hydrochloride Lamivudine Levodopa with Benserazide Levodopa with Benserazide Levodopa with Benserazide Levodopa with Benserazide Levodopa with Benserazide Levonorgestrel Lignocaine Lignocaine Lithium Carbonate Magnesium Sulphate Melphalan Melphalan Mesalazine Metaraminol Tartrate Metronidazole Metronidazole Mitozantrone Naloxone Hydrochloride

Line Item Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cinchocaine hydrochloride 5 mg per g Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and cinchocaine hydrochloride 1 mg Crm 0.1% with lignocaine hydrochloride 2% Suppos 1 mg with lignocaine hydrochloride 40 mg Inj 24 mg per ml Inj 20 mg per ml, 2 ml Inj 10 mg per ml, 1 ml Suppos 3 g or less Inj 5 mg per ml, 1 ml Inj 5 mg per ml, 10 ml Inj 500 mcg with 2.5 mg neostigmine per ml, 1 ml Inj 20 mg per ml, 1 ml Scalp lotn 0.1% Oint 0.05% with cinchocaine hydrochloride 0.05% per g Suppos 5 mg with cinchocaine hydrochloride 5 mg per g Oint 0.25% with lignocaine hydrochloride 5% aluminium subacet 3.5% and zinc oxide 18% Suppos 0.25% with lignocaine hydrochloride 5% aluminium subacet 3.5% and zinc oxide 18% Tab 400 mg Tab 600 mg Tab long-acting 800 mg Tab 10 mg Tab 25 mg Inj 500 mg with cilastatin 500 mg Inj 50 mg per ml, 10 ml Inj 100 mg per ml, 2 ml Inj 100 mg per ml, 10 ml Inj 50 mg per ml, 5 ml preservative free Inj 100 mg per ml, 2 ml preservative free Oral liq 5 mg per ml Cap 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg Cap long-acting 100 mg with benserazide 25 mg Tab dispersible 50 mg with benserazide 12.5 mg Tab 30 mcg Topical soln 4% Viscous soln 2% Tab long-acting 400 mg Paste (pack size 100 g or less) Inj 50 mg Tab 2 mg Tab 400 mg Inj 10 mg per ml, 1 ml Tab 200 mg Tab 400 mg Inj 2 mg per ml, 5 ml Inj 400 mcg per ml, 1 ml

A351107 - qA15909

Page 3 of 4

---

Chemical Name Neostigmine Nicotinic Acid Paraldehyde Pentostatin (deoxycoformycin) Pethidine Hydrochloride Piroxicam Piroxicam Potassium Chloride Pravastatin Procarbazine Hydrochloride Pyridoxine Hydrochloride Pyridoxine Hydrochloride Rizatriptan Benzoate Teniposide Testosterone Thalidomide Thioguanine Thiotepa Tolcapone Tretinoin Wool Fat with Mineral Oil Zidovudine (AZT) with Lamivudine Zinc Zinc

Line Item Inj 2.5 mg per ml, 1 ml Tab 500 mg Inj 5 ml Inj 10 mg Inj 50 mg per ml, 1.5 ml Tab dispersible 10 mg Tab dispersible 20 mg Inj 75 mg per ml, 10 ml Tab 80 mg Cap 50 mg Tab 25 mg Tab 50 mg Wafer 10 mg Inj 10 mg per ml, 5 ml Transdermal patch 2.5 mg per day Cap 50 mg Tab 40 mg Inj 15 mg Tab 100 mg Cap 10 mg Lotn hydrous 3% with mineral oil Tab 300 mg with lamivudine 150 mg Crm BP Crm BP (pack size 20 g or less)

For the remaining products on the Invitation to Tender dated 21 December 2007, the Invitation to Tender dated 23 December 2008 and the Invitation to Tender dated 4 December 2009 where no announcement has been made, either a decision is still pending, or is provisional and subject to the product gaining market approval and having sufficient stock. We will keep you informed regarding any changes for the remaining tender products as further decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.

A351107 - qA15909

Page 4 of 4